NovaBridge Biosciences (NBP) Receivables - Net (2020 - 2022)

NovaBridge Biosciences (NBP) has reported Receivables - Net for 3 consecutive years, with -$5.6 million the latest figure, recorded in Q2 2022.

• Quarterly Receivables - Net fell 131.96% year-over-year to -$5.6 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was -$5.6 million (down 131.96% YoY) and the FY2022 annual result came in at $4.3 million, down 12.22% from the prior year.
• Receivables - Net slipped to -$5.6 million in Q2 2022 per NBP's latest filing, from $4.9 million in the prior quarter.
• Over the last five years, Receivables - Net for NBP reached as high as $34.3 million in Q4 2020 and fell as low as -$5.6 million in Q2 2022.
• A 3-year average of $7.8 million and a median of $1.3 million in 2021 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2021 — Receivables - Net slumped 85.6% — and 2022, when it tumbled 131.96%.
• Year by year, Receivables - Net stood at $34.3 million in 2020, then sank by 85.6% to $4.9 million in 2021, then tumbled by 212.67% to -$5.6 million in 2022.
• According to Business Quant data, Receivables - Net over the past three periods registered -$5.6 million, $4.9 million, and -$2.4 million for Q2 2022, Q4 2021, and Q2 2021 respectively.